E
Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
E
Sell
2/27/2025Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 2/27/2025 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.7364 to -$1.501, the quick ratio declined from 16.82 to 13.61, and EBIT declined 5.98% from -$63.85M to -$67.66M.
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 2/27/2025 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.7364 to -$1.501, the quick ratio declined from 16.82 to 13.61, and EBIT declined 5.98% from -$63.85M to -$67.66M.
D
Sell
2/13/2025Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 2/13/2025 due to an increase in the volatility index.
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 2/13/2025 due to an increase in the volatility index.
E
Sell
1/27/2025Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 1/27/2025 due to a decline in the total return index and volatility index.
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 1/27/2025 due to a decline in the total return index and volatility index.
D
Sell
1/6/2025Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index and valuation index.
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index and valuation index.
E
Sell
12/10/2024Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 12/10/2024 due to a decline in the total return index, volatility index and valuation index.
Bicycle Therapeutics plc (BCYC) was downgraded to E+ from D- on 12/10/2024 due to a decline in the total return index, volatility index and valuation index.
D
Sell
3/14/2023Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D on 03/14/2023.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D on 03/14/2023.
D
Sell
3/3/2023Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 3/3/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 416.25% from -$5.87M to -$30.31M, the quick ratio declined from 8.97 to 6.76, and debt to equity increased from 0.11 to 0.12.
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 3/3/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 416.25% from -$5.87M to -$30.31M, the quick ratio declined from 8.97 to 6.76, and debt to equity increased from 0.11 to 0.12.
D
Sell
2/9/2023Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 02/09/2023.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 02/08/2023.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 02/08/2023.
D
Sell
12/30/2022Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 12/30/2022 due to an increase in the volatility index and valuation index.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 12/30/2022 due to an increase in the volatility index and valuation index.
D
Sell
12/15/2022Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 12/15/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Total revenue declined 30.56% from $4.38M to $3.04M, EBIT declined 9.01% from -$27.3M to -$29.76M, and the quick ratio declined from 9.65 to 8.97.
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 12/15/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Total revenue declined 30.56% from $4.38M to $3.04M, EBIT declined 9.01% from -$27.3M to -$29.76M, and the quick ratio declined from 9.65 to 8.97.
D
Sell
8/4/2022Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 8/4/2022 due to an increase in the total return index.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 8/4/2022 due to an increase in the total return index.
D
Sell
7/19/2022Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 7/19/2022 due to a decline in the total return index, volatility index and valuation index.
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 7/19/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 5/16/2022 due to an increase in the valuation index.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 5/16/2022 due to an increase in the valuation index.
D
Sell
5/13/2022Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 5/13/2022 due to a decline in the solvency index, growth index and total return index. Operating cash flow declined 152.99% from -$10.44M to -$26.4M, EBIT declined 51.93% from -$18.02M to -$27.38M, and earnings per share declined from -$0.6298 to -$0.9311.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 5/13/2022 due to a decline in the solvency index, growth index and total return index. Operating cash flow declined 152.99% from -$10.44M to -$26.4M, EBIT declined 51.93% from -$18.02M to -$27.38M, and earnings per share declined from -$0.6298 to -$0.9311.
D
Sell
5/4/2022Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 05/04/2022.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 05/04/2022.
D
Sell
5/1/2022Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 5/1/2022 due to a decline in the total return index and volatility index.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 04/21/2022.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 04/21/2022.
D
Sell
4/20/2022Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 4/20/2022 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 148.05% from $21.72M to -$10.44M, EBIT declined 26.09% from -$14.29M to -$18.02M, and total revenue declined 12.97% from $4.33M to $3.77M.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 4/20/2022 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 148.05% from $21.72M to -$10.44M, EBIT declined 26.09% from -$14.29M to -$18.02M, and total revenue declined 12.97% from $4.33M to $3.77M.
D
Sell
11/9/2021Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 11/9/2021 due to an increase in the volatility index and total return index.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D- on 11/9/2021 due to an increase in the volatility index and total return index.
D
Sell
11/8/2021Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
Bicycle Therapeutics plc (BCYC) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
D
Sell
6/21/2021Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 6/21/2021 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 6.51 to 10.07.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 6/21/2021 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 6.51 to 10.07.
D
Sell
1/20/2021Downgrade
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 1/20/2021 due to a decline in the valuation index.
Bicycle Therapeutics plc (BCYC) was downgraded to D from D+ on 1/20/2021 due to a decline in the valuation index.
D
Sell
12/1/2020Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 12/1/2020 due to a substantial increase in the growth index, total return index and solvency index. Total revenue increased 144.56% from $1.57M to $3.84M, the quick ratio increased from 6.37 to 9.31, and earnings per share increased from -$0.6702 to -$0.5219.
Bicycle Therapeutics plc (BCYC) was upgraded to D+ from D on 12/1/2020 due to a substantial increase in the growth index, total return index and solvency index. Total revenue increased 144.56% from $1.57M to $3.84M, the quick ratio increased from 6.37 to 9.31, and earnings per share increased from -$0.6702 to -$0.5219.
D
Sell
6/2/2020Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the total return index.
Bicycle Therapeutics plc (BCYC) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the total return index.
D
Sell
2/4/2020Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 2/4/2020 due to an increase in the total return index.
Bicycle Therapeutics plc (BCYC) was upgraded to D- from E+ on 2/4/2020 due to an increase in the total return index.
E
Sell
1/7/2020Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to E+ from E on 1/7/2020 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from -$1.3999 to -$0.5297.
Bicycle Therapeutics plc (BCYC) was upgraded to E+ from E on 1/7/2020 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from -$1.3999 to -$0.5297.
E
Sell
11/5/2019Upgraded
Bicycle Therapeutics plc (BCYC) was upgraded to E from E- on 11/5/2019 due to an increase in the total return index and efficiency index.
Bicycle Therapeutics plc (BCYC) was upgraded to E from E- on 11/5/2019 due to an increase in the total return index and efficiency index.
E
Sell
8/19/2019None
Bicycle Therapeutics plc (BCYC) was downgraded to E- from U on 08/19/2019.
Bicycle Therapeutics plc (BCYC) was downgraded to E- from U on 08/19/2019.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
